|
Headquartered in Geneva, Switzerland, the largest subsidiary of Merck Group of Merck - Serono has announced that the European Commission has approved the company's new drug Kuvan - can be used for the treatment of phenylketonuria (PKU) or high Hyperlipemia phenylalanine (HPA) - listed. Prior to the European drug Kuvan Review Board issued a certificate of orphan drugs. Orphan Drug refers to a rare disease, but less commercial value, there is no willingness to invest in the development of pharmaceutical drugs. In the United States or the European Union Orphan Drug qualified to obtain drugs, tax cuts and other concessions available. the vice president Roberto Gradnik said: "PKU is a Genetic and disease , if the patient did not strictly control the diet, PKU can lead to serious brain damage to children, leading to temporary or even permanent adult damage. Europe has not been available for PKU drug treatment. Kuvan listing will provide for the effective treatment of patients with , patients with better control of blood phenylalanine levels, help to improve the quality of life in patients with volume , and may ultimately reduce the risk of brain damage sustained. " Europe about 35,000 people were diagnosed with PKU or HPA, PKU or HPA low morbidity, less the number of patients, it is a rare disease . Because patients with blood in the high phenylalanine level, therefore, strictly limit the high level of phenylalanine food , such as meat, fish, nuts , as well as some dairy products vegetables and fruit and added amino acids in patients with diet is still the best choice at present the only therapy, but it may cause long-term patients nutrition bad. two major international double-blind, randomized, placebo-controlled phase โ
|
